Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Every story we pull is tagged to the disease it’s about — so you can filter to your condition and read only what matters.
Showing news related to
protein c pathway dysfunction in antiphospholipid syndrome a way out of the rut
Original title: “Protein C pathway dysfunction in antiphospholipid syndrome: a way out of the rut?”
immune thrombocytopenia is rare in patients with antiphospholipid syndrome without systemic lupus erythematosus insights from a series of 351 patients
Original title: “Immune thrombocytopenia is rare in patients with antiphospholipid syndrome without systemic lupus erythematosus: insights from a series of 351 patients.”
NIH-funded clinical trial shows that the new approach could also decrease time in the hospital.
Original title: “Symptom-based approach treats opioid withdrawal in newborns with minimal drug exposure ”
An incredible success story for CAR-T cell therapy. Car-T cell therapy is “borrowed” from cancer treatment. Image in Creative Commons. A 47-year-old woman in Germany had spent more than a decade battling three severe autoimmune diseases at once: autoimmune hemolytic anemia (AIHA), immune thrombocytopenia (ITP), and antiphospholipid syndrome (APS). The team turned to CAR-T cell therapy. For the last decade, this technology has gained praise as a cure for blood cancers like leukemia. ... Stay ahead with ZME Science and subscribe. Please check your inbox and confirm your subscription. Discarded Thymus glands offer new hope for people with autoimmune disease · New treatment boosts survival rates for lung cancer patients Fabian Müller at the University Hospital of Erlangen in Germany in 2025, she was “refractory,” a clinical word that often means “we have nothing left to try.” She required daily infusions of blood. But there was one silver lining. The common denominator in all three of her diseases was a rogue faction of B cells. Then, doctors decided to try an extreme solution, a reboot of her entire immune system. They used CAR-T cell therapy, a therapy that has shown great promise in cancer treatment.
Original title: “Revolutionary Therapy Cured Three "Incurable" Autoimmune Diseases in a Patient”
criterion validity of the eular antiphospholipid syndrome disease activity score eapsdas
Original title: “Criterion validity of the EULAR Antiphospholipid Syndrome Disease Activity Score (EAPSDAS).”
intrapancreatic cysts as a diagnostic clue in antiphospholipid syndrome a report of three cases
Original title: “Intrapancreatic cysts as a diagnostic clue in antiphospholipid syndrome: a report of three cases.”